NCI and all five cooperative groups that make up the National Clinical Trials Network have launched a large-scale precision medicine initiative that will match cancer patients with early-phase clinical trials testing novel drug combinations that target specific tumor alterations.
Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.
